AB

ST

RA

CT

S

Heart, Lung and Circulation Abstracts S1732008;17S:S1–S209

Conclusions: This prospective multicentre registrydemonstrates that eptifibatide was safe and effective onintroduction into clinical practice, was commonly used foroff-label indications and for time periods different to man-ufacturer’s recommendations. Monitoring introductionof a new drug through a cooperative multicentre registryis a useful tool for quality assurance and assessment ofclinical standards of care.

doi:10.1016/j.hlc.2008.05.410

410A 2 × 2 Factorial Design Randomised Control TrialAssessing the Efficacy of High Pressure Coronary StentDeployment and Post-dilation to Achieve Relative Over-size Compared to Nominal Stent Deployment and Sizingin Patients at High Risk for Re-stenosis Using theEndeavor Drug-eluting Stent Versus Bare Metal Stents:The HEADROOM trial—Report of the First 100 Patients

Joseph Matthews 1,2,3,4,∗, Mark Pitney 1,2,3,4, NigelJepson 1,2,3,4, Robert Giles 1,2,3,4, Daniel Friedman 1,2,3,4,Roger Allan 1,2,3,4, Warren Walsh 1,2,3,4, Antony Lau 1,2,3,4,Sze-yuan Ooi 1,2,3,4

1 Eastern Heart Clinic, Randwick, Australia; 2 Prince of Wales,Randwick, Australia; 3 Sutherland Heart Clinic, Sutherland,Australia; 4 The Sutherland Hospital, Sutherland, Australia

BmOspMtFfdwieaepcmtPtosAMeFmvo

Conclusion: Early results suggest reduction in TLR withendeavour in this group.

doi:10.1016/j.hlc.2008.05.411

411Feasibility and Safety of Erythropoietin (EPO) Adminis-tration in Patients with Acute Myocardial Infarction toImprove Cardiac Function and Remodelling: Pilot Study

Joseph Matthews 1,2,3,∗, Mark Pitney 1,2,3, JasonKovacic 1,2,3, Robert Lindeman 1,2,3, Eugene Loh 1,2,3,Nigel Jepson 1,2,3, Greg Cranney 1,2,3, Sze-yuan Ooi 1,2,3

1 Eastern Heart Clinic, Randwick, Australia; 2 Prince Of Wales,Randwick, Australia; 3 St. Vincents Hospital, Sydney, Australia

Background: Research into the cardio-protective effectsof EPO in animal models of myocardial infarction isan area of increasing interest, with studies reporting areduction in infarct size, cell apoptosis and improved neo-vascularization. We now report the results of a safety trialadministering EPO to humans during the post infarctperiod.Methods: This was a single centre safety trial conductedwith Ethics committee and TGA approval. Initially inclu-sion criteria were patients with EF < 40% within 24 hof primary angioplasty for AMI, this was increased toEF < 50% within 48 h to improve enrolment. Exclusion cri-tA1cEaRO1TceCwato

d

4CS

NSD

BnT

ackground: The use of drug eluting stents in “inter-ediate” restenosis risk patients remains controversial.ver-sizing a stent to reduce restenosis is unproven. This

tudy aimed to investigate these practices. We report onrogress of the first 100 patients.ethods: Five hundred patients will be enrolled across

wo centres into a 2 × 2 factorial design randomised trial.or inclusion patients must have two risks for restenosisrom a list of either clinical (diabetes, acute coronary syn-rome) or angiographic (ostial, length > 18 mm, calcium,idth ≤2.5 mm, lesion B2/C) criteria. Randomisation is

nto either over-size (OS) vs. nominal-size, and then drugluting (endeavour) vs. bare metal. Oversize is defineds a final target lesion diameter 10–20% greater than ref-rence vessel diameter. A maximum of 2 planned stentser patient is permitted. The primary endpoint is clini-ally driven target lesion revascularisation (TLR) over 12onths. Secondary endpoints include MACE and stent

hrombosis.rocedural results: In the 1st 100 pts, 52 were randomised

o received endeavour stents and 48 bare metal. A totalf 118 lesions were treated with an average reference ves-el diameter of 2.95 = −0.6 mm. Lesion length was 18 mm.ll lesions were successfully stented with no proceduralACE. Over-sizing did not increase periprocedural Tp

levation (mean 10 h Trop I 0.6).ollow up Results: 70(%) patients follow up of over 6onths, TLR has occurred in 5/48 bare metal patients

s. 0/52 endeavour (p = 0.02). No stent thrombosis hasccurred.

eria included any previous history of LV dysfunction.ll patients received a single intravenous dose of Eprex

0,000 i.u. within 48 h of primary angioplasty. Bloods wereollected at baseline, day 7, 14, 30, 3 months and 6 months.ndpoints included mortality and hyper-viscosity eventsnd MACE at six months.esults: Fourteen patients were enrolled from July 2006 toctober 2007, with to date 6-month follow-up for 11/14.

3/14 were LAD infarcts, 1/14 RCA, with mean EF 44%.here was no significant change in red cell or reticulocyteount or haematocrit. There were no significant adversevents.onclusion: A 10,000 u dose of IV Eprex given to patientsith large myocardial infarcts in the period immediately

fter primary angioplasty is safe and feasible. Dose escala-ion and phase II studies are required to measure efficacyf EPO therapy for myocardial infarction.

oi:10.1016/j.hlc.2008.05.412

12omplications of Coronary Angiography in a Real-Worldetting: 8-year Experience

amal Wijeisnghe ∗, Christopher Nunn, Cherianebastian, Spencer Heald, Hugh McAlister, Gerardevlin

Waikato Hospital, Hamilton, New Zealand

ackground: The risk of major complications during coro-ary angiography is not well documented in New Zealand.he aim of this study was to evaluate the incidence of